<DOC>
	<DOCNO>NCT00070629</DOCNO>
	<brief_summary>Eligible patient randomize ratio 2:1 receive either chemotherapy ( taxane platinum compound ) plus CPG 7909 Injection chemotherapy alone . Protocol therapy administer disease progression intolerable toxicity . CpG 7909 Injection administer subcutaneously , Weeks 2 3 three-week cycle ( day 8 15 ) chemotherapy administer Week 1 ( Day 1 ) . Patients undergo complete disease evaluation end every treatment cycle disease progression .</brief_summary>
	<brief_title>CPG 7909 Injection Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell lung cancer beyond surgical cure metastatic ( Stage IIIB IV accord AJCC ) . Patients must measurable disease accord RECIST criterion . Prior treatment chemotherapy ; patient may receive prior radiotherapy . Patients suspect known CNS metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>lung cancer</keyword>
</DOC>